Diabetes Dialogue: Tirzepatide's New CV Indication and the STAREE Statin Trial

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Insulin resistance and cardiovascular risk sit at the center of nearly every conversation in modern diabetes care, and 2 recent developments push this conversation forward. Co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, open this episode with the newly approved cardiovascular indication for tirzepatide, then turn to fresh data on statin therapy in adults over 70. Both topics carry immediate implications for how clinicians counsel patients on risk reduction across the lifespan.

Tirzepatide Gains FDA Approval for Cardiovascular Risk Reduction

On August 28, 2026, the US Food and Drug Administration approved tirzepatide, marketed as Mounjaro, to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events.¹ The approval covers cardiovascular death, nonfatal heart attack, and nonfatal stroke.

Isaacs notes some clinicians expected this approval to be uncertain because the pivotal SURPASS-CVOT trial compared tirzepatide with dulaglutide rather than placebo and found noninferiority rather than superiority. Bellini points out dulaglutide already carries its own cardiovascular indication, so a noninferior result still places tirzepatide on equal footing with an agent already proven to reduce cardiovascular risk. The trial enrolled > 13,000 participants across 30 countries, giving the finding a broad and diverse evidence base.

Isaacs walks through a pair of additional analyses strengthening the case for approval. An imputed placebo comparison, built through statistical modeling rather than a true placebo arm, suggested tirzepatide would have shown superiority had an ethical placebo-controlled design been possible given the established benefit of comparator agents. A separate 5-point MACE analysis presented by cardiologist Steve Nissen, MD, of Cleveland Clinic, also favored tirzepatide once additional cardiovascular outcomes were incorporated beyond the original 3-point composite.

Isaacs highlights the approval covers patients at high risk for cardiovascular events rather than requiring established cardiovascular disease, a distinction she expects will broaden access. Bellini adds this framing captures a wide swath of everyday patients, since diabetes, hypertension, elevated cholesterol, and obesity all confer elevated risk on their own.

The hosts also raise an open mechanistic question: whether the cardiovascular benefit stems from tirzepatide's GLP-1 activity, its GIP activity, or both. Isaacs notes dulaglutide achieves cardiovascular benefit with considerably less glucose-lowering and weight-loss potency, raising questions about how much of tirzepatide's effect traces to the GIP component as dual and triple agonists enter development.

Bellini emphasizes patient selection remains individualized regardless of the new indication, since tolerability and prior response still guide the choice between agents. The discussion closes by noting semaglutide and tirzepatide carry distinct indications beyond cardiovascular risk, including kidney disease and MASH for semaglutide and sleep apnea for tirzepatide, keeping regimen selection a multifactorial decision.

STAREE Trial Supports Statin Use for Primary Prevention After Age 70

Statin therapy in older adults has long lacked robust trial evidence, since patients older than 70 have historically been excluded or underrepresented in pivotal statin studies. The STAREE trial, published in the New England Journal of Medicine, randomly assigned nearly 10,000 adults with a mean age of 74.7 years to atorvastatin 40 mg or placebo.²

Bellini highlights the balanced enrollment of 52% women, addressing a long-standing gap in sex representation within statin research. Over a median follow-up of 5.9 years, atorvastatin reduced major cardiovascular events by 30% compared with placebo, a finding both hosts describe as clinically meaningful for a low-cost, generic medication.

Isaacs points out disability-free survival did not differ significantly between groups, suggesting age alone should not automatically dictate statin initiation. She reinforces the value of individualized, shared decision-making for patients with limited life expectancy or significant comorbidity burden.

Bellini adds serious adverse events occurred at similar rates in both arms, at 2.7%, countering the common perception statins routinely cause significant side effects in older patients. She encourages clinicians to try alternative statins before concluding a patient cannot tolerate the drug class. The hosts close by addressing dementia risk directly: daily statin therapy did not significantly change dementia rates over nearly 6 years, a neutral finding they frame as reassuring given ongoing patient concerns.

Editors’ Note: Disclosures for Isaacs include Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

References

1. Eli Lilly and Company. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Press release. August 28, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular

2. Zoungas S, Wolfe R, Moran C, et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N Engl J Med. Published online August 28, 2026. doi:10.1056/NEJMoa2607314